Batavia Biosciences Announces Collaboration with Phoenix Nest Inc. to Accelerate Development of Therapeutics for Sanfilippo Syndrome

The collaboration aims to fast-track the development and production of recombinant human N-acetylglucosamine-6-sulfatase (rhGNS) for treatment of Sanfilippo syndrome, a rare genetic disorder.
Batavia Biosciences - Favicon

Woburn, MA, 16 October 2023 — Batavia Biosciences, a leading global Contract Development and Manufacturing Organization, announced a new partnership with Phoenix Nest Inc., a bespoke biotech company focusing on treating ultra-rare diseases. The collaboration aims to fast-track the development and production of recombinant human N-acetylglucosamine-6-sulfatase (rhGNS) for treatment of Sanfilippo syndrome, a rare genetic disorder.

Batavia Biosciences will perform crucial process and analytical development for Phoenix Nest Inc. This work will enable the future production of rhGNS for toxicity studies and establishing a scalable, Good Manufacturing Practice (GMP)-compatible process.

“We are very pleased that Phoenix Nest decided to contract Batavia Biosciences based on our proven track record and technological expertise. We are honored to collaborate and provide solutions for patients battling Sanfilippo syndrome.” says Peter Abbink, PhD, Managing Director at Batavia Biosciences, Inc., located in Woburn, MA.

The need for high-quality, specialized therapeutics for Sanfilippo syndrome remains an urgent priority. Affected individuals often face severe neurological symptoms with limited treatment options. This collaboration aims to advance the scientific understanding and accelerate the development of treatments for this devastating disease.

“Phoenix Nest is developing therapies for Mucopolysaccharidosis type III (MPS III), also referred to as Sanfilippo Syndrome. We made significant progress towards the development of an enzyme replacement therapy for Sanfilippo syndrome type D, including an observations study [NCT05648851] in MPS IIID patients. We are excited about our collaboration with Batavia for our enzyme manufacturing and scale-up development” stated Jill Wood, CEO, Phoenix Nest Inc.

About Phoenix Nest Inc.

Phoenix Nest Inc. is a bespoke biotechnology company specializing in developing innovative therapies for ultra-rare diseases, with a primary focus on Sanfilippo syndrome. Sanfilippo syndrome (Mucopolysaccharidosis III), a set of genetic neurodevelopmental disorders that result in progressive neurological, developmental, and physical regression. The impacted individuals require life-long medical and supportive care as there are no approved cures or treatments.  Phoenix Nest is the proud recipient of several Small Business Innovation Research grants from the National Institute of Health. Through funding from the NIH under Award Number U44NS089061, we have been able to facilitate the research in academic labs and licensed these programs for development and translation to clinical interventions.

About Batavia Biosciences

Batavia Biosciences significantly contributes to ease human suffering from infectious diseases, cancer, and rare diseases by leveraging our innovative technologies and in-depth know-how. We do this for viral vaccines and cell and gene therapies at all stages of the development trajectory, from the transition into early clinical studies, to navigating late-stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success. The company operates state-of-the-art development and manufacturing facilities in Europe and the US and, as part of the CJ CheilJedang global family, is building a strong position in global health with its strategic partners worldwide.

Media Contacts

Phoenix Nest Inc.

Jill Wood, CEO

jwood@phoenixnestbiotech.com

Batavia Biosciences

Peter Abbink, Managing Director

p.abbink@bataviabiosciences.com

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression